Literature DB >> 23397296

The effect of nasal tramazoline with dexamethasone in obstructive sleep apnoea patients.

Ioannis Koutsourelakis1, Aliki Minaritzoglou, Georgios Zakynthinos, Emmanouil Vagiakis, Spyros Zakynthinos.   

Abstract

Although there is a strong correlation between oral/oro-nasal breathing and apnoea/hypopnoea index in patients with obstructive sleep apnoea and normal nasal resistance at wakefulness, it remains unknown whether the pharmacological prevention of potential nasal obstruction during sleep could decrease oral/oro-nasal breathing and increase nasal breathing and subsequently decrease the apnoea/hypopnoea index. This study evaluated the effect of a combination of a nasal decongestant with corticosteroid on breathing route pattern and apnoea/hypopnoea index. 21 patients with obstructive sleep apnoea (mean apnoea/hypopnoea index 31.1 events per hour) and normal nasal resistance at wakefulness were enrolled in a randomised crossover trial of 1 weeks' treatment with nasal tramazoline and dexamethasone compared with 1 weeks' treatment with nasal placebo. At the start and end of each treatment period, patients underwent nasal resistance measurement and overnight polysomnography with attendant measurement of breathing route pattern. Nasal tramazoline with dexamethasone was associated with decrease in oral/oro-nasal breathing epochs and concomitant increase in nasal breathing epochs, and mean decrease of apnoea/hypopnoea index by 21%. The change in nasal breathing epochs was inversely related to the change in apnoea/hypopnoea index (Rs=0.78; p<0.001). In conclusion, nasal tramazoline with dexamethasone in OSA patients with normal nasal resistance at wakefulness can restore the preponderance of nasal breathing epochs and modestly improve apnoea/hypopnoea index.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23397296     DOI: 10.1183/09031936.00142312

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  7 in total

1.  A randomised controlled trial of nasal decongestant to treat obstructive sleep apnoea in people with cervical spinal cord injury.

Authors:  Nirupama S Wijesuriya; Danny J Eckert; Amy S Jordan; Rachel Schembri; Chaminda Lewis; Hailey Meaklim; Lauren Booker; Doug Brown; Marnie Graco; David J Berlowitz
Journal:  Spinal Cord       Date:  2019-02-13       Impact factor: 2.772

Review 2.  [Treating nasal obstruction in obstructive sleep apnea patients].

Authors:  T Verse; S Wenzel
Journal:  HNO       Date:  2017-02       Impact factor: 1.284

3.  Nasal Resistance Is Elevated in People with Tetraplegia and Is Reduced by Topical Sympathomimetic Administration.

Authors:  Laura Gainche; David J Berlowitz; Mariannick LeGuen; Warren R Ruehland; Fergal J O'Donoghue; John Trinder; Marnie Graco; Rachel Schembri; Danny J Eckert; Peter D Rochford; Amy S Jordan
Journal:  J Clin Sleep Med       Date:  2016-11-15       Impact factor: 4.062

4.  Impact Of Spinal Cord Injury On Sleep: Current Perspectives.

Authors:  Abdulghani Sankari; M Safwan Badr; Jennifer L Martin; Najib T Ayas; David J Berlowitz
Journal:  Nat Sci Sleep       Date:  2019-10-15

Review 5.  Targeting Endotypic Traits with Medications for the Pharmacological Treatment of Obstructive Sleep Apnea. A Review of the Current Literature.

Authors:  Luigi Taranto-Montemurro; Ludovico Messineo; Andrew Wellman
Journal:  J Clin Med       Date:  2019-11-02       Impact factor: 4.241

6.  Comparison of hemostatic effect and safety between epinephrine and tramazoline during nasotracheal intubation: a double-blind randomized trial.

Authors:  Aiji Sato-Boku; Yoshiki Sento; Yuji Kamimura; Eisuke Kako; Masahiro Okuda; Naoko Tachi; Yoko Okumura; Mayumi Hashimoto; Hiroshi Hoshijima; Fumihito Suzuki; Kazuya Sobue
Journal:  BMC Anesthesiol       Date:  2021-09-30       Impact factor: 2.217

7.  Obstructive Sleep Apnoea Modulates Airway Inflammation and Remodelling in Severe Asthma.

Authors:  Camille Taillé; Anny Rouvel-Tallec; Maria Stoica; Claire Danel; Monique Dehoux; Viviana Marin-Esteban; Marina Pretolani; Michel Aubier; Marie-Pia d'Ortho
Journal:  PLoS One       Date:  2016-03-02       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.